Nonclinical precedent Request an invite

Blincyto: genotox, carcinogenicity and repro: done or skipped?

blinatumomab · CD19 x CD3
Genotoxicity
Not conducted (ICH S6(R1); protein of natural amino acids)
“In vitro and in vivo genotoxicity studies were not performed in accordance with ICH S6 (R1).”
✓ VerifiedEMA assessment report, p. 31Source ↗
Carcinogenicity
Not conducted (ICH S9, advanced cancer indication)
“As it is being developed for advanced cancer indications, no carcinogenicity studies have been conducted, in accordance with ICH S9.”
✓ VerifiedEMA assessment report, p. 31Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Mouse EFD with surrogate: placental transfer, no embryo-fetal toxicity or teratogenicity; no fertility studies
“Studies in mice using the surrogate showed no drug-related effects in male or female reproductive organs and did not reveal any embryo-fetal toxicity or teratogenicity.”
✓ VerifiedFDA pharmacology/toxicology review, p. 5Source ↗
Safety pharmacology
CNS (Irwin, ICV infusion) and respiratory studies in mice with surrogate; CV in chimpanzee tox studies
“To evaluate the potential effects on the central nervous system (CNS), two CNS safety pharmacology studies were conducted with the murine surrogate muS103new in mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 82Source ↗
Genotox: Ames
Not conducted (ICH S6)
“In vitro and in vivo genotoxicity studies were not performed in accordance with ICH S6 (R1).”
✓ VerifiedEMA assessment report, p. 31Source ↗
Genotox: in vitro mammalian
Not conducted (ICH S6)
“In vitro and in vivo genotoxicity studies were not performed in accordance with ICH S6 (R1).”
✓ VerifiedEMA assessment report, p. 31Source ↗
Genotox: in vivo
Not conducted (ICH S6)
“In vitro and in vivo genotoxicity studies were not performed in accordance with ICH S6 (R1).”
✓ VerifiedEMA assessment report, p. 31Source ↗
Carcinogenicity model
Not conducted (advanced cancer indication, ICH S9)
“As it is being developed for advanced cancer indications, no carcinogenicity studies have been conducted, in accordance with ICH S9.”
✓ VerifiedEMA assessment report, p. 31Source ↗
Carcinogenicity timing
Not required for advanced cancer indication (ICH S9)
“As it is being developed for advanced cancer indications, no carcinogenicity studies have been conducted, in accordance with ICH S9.”
✓ VerifiedEMA assessment report, p. 31Source ↗
hERG / QT
No hERG or QT data stated; cardiovascular monitoring in 6 chimpanzees showed hypotension, possibly cytokine-related
“Cardiovascular function was monitored during the toxicity studies performed with blinatumomab in a total of 6 chimpanzees. Changes in blood pressure (hypotension) were observed in some animals and may be related to a treatment-related increase in cytokine levels.”
✓ VerifiedEMA assessment report, p. 31Source ↗

Same question, other multispecifics

Bizengri

zenocutuzumab · HER2 x HER3
Not conducted (ICH S6(R1))

Columvi

glofitamab · CD20 x CD3
Not conducted (ICH S6(R1))

Elrexfio

elranatamab · BCMA x CD3
Not conducted (ICH S6(R1))

Epkinly

epcoritamab · CD20 x CD3
Not conducted (ICH S6(R1), ICH S9)

Hemlibra

emicizumab · FIXa x FX
Not conducted (ICH S6)

Imdelltra

tarlatamab · DLL3 x CD3
Not conducted (ICH S6(R1))

Kimmtrak

tebentafusp · CD3 x gp100 (TCR fusion)
Not conducted (fusion protein; ICH S6/S9)

Korjuny

catumaxomab · EpCAM x CD3
Not conducted (ICH S6(R1))

Lunsumio

mosunetuzumab · CD20 x CD3
Not conducted (ICH S6(R1))

Lynozyfic

linvoseltamab · BCMA x CD3
Not conducted (antibody not expected to interact with DNA)

Ordspono

odronextamab · CD20 x CD3
Not conducted (antibody not expected to interact with DNA)

Removab

catumaxomab · EpCAM x CD3
Not conducted (not submitted; biologic, no relevant model)

Rybrevant

amivantamab · EGFR x MET
Not conducted (not appropriate for antibodies)

Talvey

talquetamab · GPRC5D x CD3
Not conducted (ICH S6; biotechnology-derived product)

Tecvayli

teclistamab · BCMA x CD3
Not conducted (ICH S6(R1))

Vabysmo

faricimab · VEGF-A x Ang-2
Not conducted (ICH S6(R1))

Ziihera

zanidatamab · HER2 x HER2 (biparatopic)
Not conducted (ICH S6(R1), ICH S9)

Summary across all 18 multispecifics →